<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05059522</url>
  </required_header>
  <id_info>
    <org_study_id>B9991046</org_study_id>
    <secondary_id>2021-002457-29</secondary_id>
    <nct_id>NCT05059522</nct_id>
  </id_info>
  <brief_title>Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing</brief_title>
  <official_title>Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment&#xD;
      access, safety follow-up, and when applicable, overall survival follow-up for eligible&#xD;
      participants who continue to derive a benefit from study intervention in the Pfizer-sponsored&#xD;
      Avelumab parent studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      B9991046 is a master protocol that will consist of sub-studies from the following parent&#xD;
      studies:&#xD;
&#xD;
      B9991001 - NCT02603432 B9991004 - NCT02554812 B9991005 - NCT02584634 B9991009 - NCT02580058&#xD;
      B9991023 - NCT03317496 B9991025 - NCT03330405 B9991027 - NCT03472560 B9991032 - NCT03565991&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events leading to permanent discontinuation of study intervention</measure>
    <time_frame>Baseline up to approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number serious adverse events reported for all participants</measure>
    <time_frame>Baseline up to approximately 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">262</enrollment>
  <condition>Advanced Malignancies</condition>
  <condition>NSCLC</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Urothelial Cancer</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avelumab monotherapy as specified by sub-study protocol B9991001C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avelumab in combination with CMP 001, Utomilumab or PF04518600 as specified by sub-study protocol B9991004C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avelumab in combination with Loratanib as specified by sub-study protocol B9991005C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avelumab monotherapy as specified by sub-study protocol B9991009C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avelumab monotherapy or in combination with Pemetrexed as specified by sub-study protocol B9991023C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avelumab in combination with Talazoparib as specified by sub-study B9991025C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avelumab in combination with Axitinib as specified by sub-study B9991027C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Avelumab in combination with Talazoparib as specified by sub-study B9991032C.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>oral</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_label>Arm 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorlatanib</intervention_name>
    <description>oral</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talazoparib</intervention_name>
    <description>oral</description>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_label>Arm 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>IV (intravenous) infusion</description>
    <arm_group_label>Arm 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>oral</description>
    <arm_group_label>Arm 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CMP 001</intervention_name>
    <description>IT (intratumoral) or SC (subcutaneous)</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Utomilumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF04518600</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Any participant who is receiving study treatment and deriving significant clinical&#xD;
             benefit or is in the safety and/or survival follow-up period in a Pfizer-sponsored&#xD;
             Avelumab Parent Study.&#xD;
&#xD;
          2. Participants must agree to follow the reproductive criteria.&#xD;
&#xD;
          3. Participants must be willing and able to comply with all scheduled visits, treatment&#xD;
             plan, and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female participants who are pregnant or breastfeeding.&#xD;
&#xD;
          2. Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the&#xD;
             participant from inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Japanese Foundation for Cancer Research</name>
      <address>
        <city>Koto</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B9991046</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRCA Mutant Tumors</keyword>
  <keyword>ATM Mutant Tumors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Avelumab</mesh_term>
    <mesh_term>Axitinib</mesh_term>
    <mesh_term>Talazoparib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

